Last reviewed · How we verify

Rubidium-82 — Competitive Intelligence Brief

Rubidium-82 (Rubidium-82) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PET radiopharmaceutical. Area: Cardiovascular.

marketed PET radiopharmaceutical Na+/K+-ATPase pump (myocardial uptake mechanism) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Rubidium-82 (Rubidium-82) — Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC). Rubidium-82 is a positron-emitting radioisotope that accumulates in myocardial tissue proportional to blood flow, allowing visualization of cardiac perfusion via PET imaging.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rubidium-82 TARGET Rubidium-82 Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) marketed PET radiopharmaceutical Na+/K+-ATPase pump (myocardial uptake mechanism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PET radiopharmaceutical class)

  1. Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rubidium-82 — Competitive Intelligence Brief. https://druglandscape.com/ci/rubidium-82. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: